Future Medicinal Chemistry · 2019 · 12 citations · 17 references
MedicineMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular OncologyOncology PharmacologyTyrosine Kinase InhibitorsAssayBiological Evaluation ReportKinase Binding AssaysKinase InhibitorsKinase Signaling InhibitorsMet InhibitorsMet Receptor Tyrosine Kinase
Aim: Mesenchymal–epithelial transition factor (c-Met)/HGF overactivation is involved in diverse human cancers. Materials & methods: Herein, we report the synthesis and biological evaluation of thiomethylpyridine-linked triazolotriazines as c-Met kinase inhibitors. Results: Compounds 10b and 11e were more potent than crizotinib on HepG2 cells with IC50 values of 0.74 and 0.71 μM in the MTT assay, respectively. Interestingly, all of the target compounds displayed IC50 values in the range of 3.9–11.1 nM in the c-Met kinase inhibition assay which were lower than the value for crizotinib (11.1 nM). Conclusion: Target compound 10b can be considered as a leading drug candidate due to its lower IC50 values than crizotinib in both HGF-induced proliferation and c-Met kinase inhibition assays.
17
Hong Jia, Guangxiu Dai, Jianyang Weng et al. · Journal of Medicinal Chemistry · 2014 · 134 citations · Full text